Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Either RAC exam (Devices and Drugs) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS store will be under maintenance Saturday, 29 February between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 18 July 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) announced today that it has halted a clinical trial of the anti-cancer drug Revlimid (lenalidomide) due to safety concerns.
The drug, manufactured by Celgene, is a derivative of the infamous drug thalidomide, and is approved as a treatment for multiple myeloma, myelodysplastic syndrome (MDS) and mantle cell lymphoma.
However, due to its side effects, it is also subject to a rigorous Risk Evaluation and Mitigation Strategies (REMS) program that includes a Medication Guide and elements to assure safe use. For example, women taking the drug are instructed not to become pregnant four weeks before, during or after starting Revlimid.
The drug was undergoing further clinical testing to evaluate its potential therapeutic effects in patients 65 years of age and older with chronic lymphocytic leukemia (CLL), but FDA said it has now halted the Phase III trial due to "higher rates of death" in the treatment group receiving Revlimid versus the group treated with chlorambucil.
"The clinical trial is unlikely to achieve its main objective to reduce the amount of time for the leukemia to progress or the patient to die," FDA explained in a statement. Data released by FDA showed a 92% increased risk of death compared to chlorambucil-an increase of 16 deaths (34 versus 18) overall.
In a statement, Celgene said confirmed the cessation of the trial, named the ORIGIN Trial, as a result of FDA's 12 July 2013 clinical hold. "All clinical investigators in ongoing chronic lymphocytic leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly," the company said.
Celgene added that "No specific causality for this imbalance has been identified to date," but that trial results would be presented at an unspecified upcoming medical conference.
FDA Notice
Celgene Statement
Regulatory Focus newsletters
All the biggest regulatory news and happenings.